EP
ATYR

Essential Partners’s aTyr Pharma ATYR Stock Holding History

Essential Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486 Sell
815
-803
-50% -$525 ﹤0.01% 2483
2026
Q1 		$1.26K Buy
1,618
+1,443
+825% +$1.22K ﹤0.01% 2170
2025
Q4 		$137 Buy
+175
New +$144 ﹤0.01% 2507

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's ATYR Position: Q2 2026 in Review

Essential Partners reduced its aTyr Pharma (ATYR) stake by 50% in Q2 2026, selling an estimated $525 and leaving 815 shares worth $486. The position accounts for ﹤0.01% of the portfolio, ranked #2483.

Essential Partners first reported a position in ATYR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.26K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Essential Partners held 815 shares of aTyr Pharma worth $486 as of Q2 2026.
  • Essential Partners sold 803 aTyr Pharma shares in Q2 2026, an estimated $525.
  • aTyr Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2483 holding.
  • Essential Partners first reported a position in aTyr Pharma in Q4 2025 and has held it in 3 quarters since.
  • Essential Partners's aTyr Pharma position peaked at $1.26K in Q1 2026.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.